Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 03, 2015 2:11 AM ET

Life Sciences Tools and Services

Company Overview of Metamark Genetics, Inc.

Company Overview

Metamark Genetics, Inc., a biotechnology company, develops function-based, prognostic and diagnostic tests focusing on enhancing cancer care. The company’s genomic and proteomic discovery platforms develop solutions for various disease areas, such as prostate, bladder, colon, and breast cancers. It also provides specialty urological pathology testing services comprising prostate biopsy; triple stain; assessment of loss of PTEN function; ProMark, a prostate cancer prognostic test that differentiates indolent from aggressive disease; urine cytology; FISH molecular cytology; and other uropathology services to urologists, pathologists, and their patients in the United States. In addition, the co...

245 First Street

10th Floor

Cambridge, MA 02142

United States

Founded in 2007





Key Executives for Metamark Genetics, Inc.

Chief Executive Officer, President and Director
Co-Founder and Chairman
Age: 77
Co-Founder, Director and Scientific & Clinical Advisor
Age: 72
Co-Founder, Consultant and Scientific & Clinical Advisor
Senior Vice President of Clinical Operations
Compensation as of Fiscal Year 2015.

Metamark Genetics, Inc. Key Developments

Metamark Appoints Jerome Richie as Chief Medical Officer, Effective July 1, 2015

Metamark has appointed Dr. Jerome Richie as its chief medical officer. Richie will join the leadership team effective July 1, retiring from his current role of chief emeritus of Harvard program in Urology at Brigham and Women's Hospital and a surgery professor at Harvard Medical School.

Metamark Appoints Jerome P. Richie, M.D. as Chief Medical Officer, Effective July 1, 2015

Metamark announced that Jerome P. Richie, M.D. will join company's executive leadership team as Chief Medical Officer, effective July 1, 2015. Dr. Richie will retire from his current roles, which he has held since 1987, as the Chief (Emeritus) of the Harvard Program in Urology (Longwood Area) at Brigham and Women's Hospital in Boston, as well as the Elliott Carr Cutler Professor of Surgery (Urology) at Harvard Medical School, on June 30. Beginning on July 1, Dr. Richie will head Metamark’s clinical development and medical affairs.

Metamark Announces Partnership with Highmark Blue Shield to Provide Access to Comprehensive Urology Diagnostics

Metamark announced that it has signed an agreement with Highmark Blue Shield to provide its 5.2 million members with in-network access to Metamark’s comprehensive suite of urology specialized diagnostic offerings. The agreement covers Highmark Blue Shield members in Delaware, Pennsylvania and West Virginia. Metamark provides access to sophisticated diagnostic and prognostic tools that enable urologists to chart their patient’s optimal treatment path throughout the continuum of prostate care.

Similar Private Companies By Industry

Company Name Region
Celerion Inc. United States
Imperial Clinical Research Services, Inc. United States
BioMedTech Laboratories, Inc. United States
Bio-Quant, Inc. United States
Thrive Bioscience, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Metamark Genetics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at